SCHEMBL6964927

SCHEMBL6964927

OC1c2ccc(F)cc2CC1N1CCN(c2cccc3c2OCCO3)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 19/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6964918 1.00 HTR1A (1.00) HTR1A
SCHEMBL6973696 1.00 HTR1A (1.00) HTR1A
SCHEMBL6964920 1.00 HTR1A (1.00) HTR1A
SCHEMBL13533194 0.93 HTR1A (1.00) HTR1A
SCHEMBL6962900 0.87 HTR1A (1.00) HTR1A
SCHEMBL6962896 0.87 HTR1A (1.00) HTR1A
SCHEMBL6963912 0.87 HTR1A (1.00) HTR1A
SCHEMBL6962894 0.87 HTR1A (1.00) HTR1A
SCHEMBL6964771 0.85 HTR1A (1.00) HTR1A
SCHEMBL8179552 0.85 HTR1A (1.00) HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0906912-B1 Indanol derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-01-08 EP claimed
CN-1218051-A New 2,3-dioxide, indanol compounds, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1999-06-02 CN claimed
EP-0906912-A1 Indanol derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1999-04-07 EP claimed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed
EP-0906912-B1 Indanol derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-01-08 EP disclosed
US-6060487-A Indanol compounds ADIR ET COMPAGNIE (FR) 2000-05-09 US disclosed
CN-1218051-A New 2,3-dioxide, indanol compounds, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1999-06-02 CN disclosed
EP-0906912-A1 Indanol derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1999-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS HTR6, GAP43, HTR5A HTR1A 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.